NASDAQ:MNTA

Momenta Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$52.48
0.00 (0.00 %)
(As of 10/2/2020)
Add
Compare
Today's Range
$52.48
$52.48
50-Day Range
$52.26
$52.49
52-Week Range
$12.21
$52.53
VolumeN/A
Average Volume1.94 million shs
Market Capitalization$6.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Momenta Pharmaceuticals logo

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MNTA
CUSIP60877T10
Phone617-491-9700
Employees131
Year FoundedN/A

Sales & Book Value

Annual Sales$23.87 million
Book Value$4.59 per share

Profitability

Net Income$-290,050,000.00
Net Margins-757.61%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$6.25 billion
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.74 out of 5 stars

Medical Sector

1258th out of 2,045 stocks

Biological Products, Except Diagnostic Industry

146th out of 177 stocks

Analyst Opinion: 1.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

Is Momenta Pharmaceuticals a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Momenta Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MNTA, but not buy additional shares or sell existing shares.
View analyst ratings for Momenta Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Momenta Pharmaceuticals?

Wall Street analysts have given Momenta Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Momenta Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company earned $6.61 million during the quarter, compared to the consensus estimate of $5.84 million. Momenta Pharmaceuticals had a negative trailing twelve-month return on equity of 61.44% and a negative net margin of 757.61%.
View Momenta Pharmaceuticals' earnings history
.

What price target have analysts set for MNTA?

10 analysts have issued twelve-month price targets for Momenta Pharmaceuticals' stock. Their forecasts range from $42.00 to $57.00. On average, they expect Momenta Pharmaceuticals' share price to reach $50.88 in the next twelve months. This suggests that the stock has a possible downside of 3.1%.
View analysts' price targets for Momenta Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the following people:
  • Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 59)
  • Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 52)
  • Dr. Santiago Arroyo, Chief Medical Officer & Sr. VP of Devel. (Age 59)
  • Mr. Bruce A. Leicher, Consultant (Age 63)
  • Mr. Scott M. Storer, Consultant

Who are some of Momenta Pharmaceuticals' key competitors?

What other stocks do shareholders of Momenta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Pfizer (PFE), ACADIA Pharmaceuticals (ACAD), ImmunoGen (IMGN) and CRISPR Therapeutics (CRSP).

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

What is Momenta Pharmaceuticals' stock price today?

One share of MNTA stock can currently be purchased for approximately $52.48.

How much money does Momenta Pharmaceuticals make?

Momenta Pharmaceuticals has a market capitalization of $6.25 billion and generates $23.87 million in revenue each year. The biotechnology company earns $-290,050,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

How many employees does Momenta Pharmaceuticals have?

Momenta Pharmaceuticals employs 131 workers across the globe.

What is Momenta Pharmaceuticals' official website?

The official website for Momenta Pharmaceuticals is www.momentapharma.com.

Where are Momenta Pharmaceuticals' headquarters?

Momenta Pharmaceuticals is headquartered at 301 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]


This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.